Fennec Pharmaceuticals (TSE:FRX) Director Chris Anigeron Rallis Sells 1,775 Shares

Key Points

• Fennec Pharmaceuticals Director Chris Anigeron Rallis sold 1,775 shares at an average price of C$12.75, totaling C$22,631.25, leading to a 3.11% decrease in ownership.
• In another recent transaction, Rallis bought 4,062 shares at an average price of C$1.70, valued at C$6,905.40.
• The company's stock price has seen fluctuations, recently trading down C$0.88 to C$12.40, with a market capitalization of C$345.12 million.

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Chris Anigeron Rallis sold 1,775 shares of the company's stock in a transaction dated Friday, October 10th. The shares were sold at an average price of C$12.75, for a total transaction of C$22,631.25. Following the sale, the director owned 55,316 shares in the company, valued at C$705,279. This represents a 3.11% decrease in their ownership of the stock.

Chris Anigeron Rallis also recently made the following trade(s):

• On Friday, October 10th, Chris Anigeron Rallis bought 4,062 shares of Fennec Pharmaceuticals stock. The shares were acquired at an average price of C$1.70 per share, for a total transaction of C$6,905.40.

Fennec Pharmaceuticals Price Performance

Shares of TSE FRX traded down C$0.88 during mid-day trading on Friday, hitting C$12.40. 305 shares of the company's stock traded hands, compared to its average volume of 1,007. The company's 50-day moving average is C$12.18 and its two-hundred day moving average is C$10.71. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The company has a market capitalization of C$345.12 million, a P/E ratio of -27.56 and a beta of 2.48. Fennec Pharmaceuticals Inc. has a 1 year low of C$5.65 and a 1 year high of C$13.83.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.